According to research published in Annals of Allergy, Asthma & Immunology, laxatives may increase allergy risk in children exposed in utero or in infancy. Specifically, children exposed to laxatives in utero or in infancy had a higher prevalence of allergic disease development later in life, including allergic rhinitis.
According to the results, early-life laxative exposure was independently associated with allergic disease development in nearly all subgroups of children (adjusted HR = 1.61; 95% CI, 1.32-1.97). The researchers found that among the L-cohort, the 5-year cumulative incidence of allergic diseases was 49.81%, compared with 41.68% for the R-cohort (P= .014).
The prevalence of allergic rhinitis (38.1% vs. 30.8%), atopic dermatitis (4.9% vs. 2.4%) and asthma (5.9% vs. 3.5%) was higher in the L-cohort, but only the difference for allergic rhinitis met statistical significance.
Laxatives allergy risk
Go To Source For Respiratory Therapy Coverage
RT delivers in-depth coverage of the clinical, regulatory, and technology landscape for respiratory therapy—and reaches more than 28,000 key decision-makers and influencers. As one of healthcare’s most important data companies, we facilitate the rapid adoption of medical devices and practice management tools into the industry.
laxatives allergy risk
Go To Source For Respiratory Therapy Coverage RT delivers in-depth coverage of the clinical, regulatory, and technology landscape for respiratory therapy—and reaches more than 28,000 key decision-makers and influencers. As one of healthcare’s most important data companies, we facilitate the rapid adoption of medical devices and practice management tools into the industry. Go To Source For Respiratory Therapy Coverage RT delivers in-depth coverage of the clinical, regulatory, and technology landscape for respiratory therapy—and reaches more than 28,000 key decision-makers and influencers. As one of healthcare’s most important data companies, we facilitate the rapid adoption of medical devices and practice management tools into the industry. Go To Source For Respiratory Therapy Coverage RT delivers in-depth coverage of the clinical, regulatory, and technology landscape for respiratory therapy—and reaches more than 28,000 key decision-makers and influencers. As one of healthcare’s most important data companies, we facilitate the rapid adoption of medical devices and practice management tools into the industry.
